Baird raised the firm’s price target on Vor Bio (VOR) to $1 from 25c and keeps a Neutral rating on the shares. The firm updated its model following the licensing of Telitacicept from RemGen for autoimmune diseases.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: